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Despite the evolving advances in clinical approaches to obesity and its inherent 
comorbidities, the therapeutic challenge persists. Among several pharmacological 
tools already investigated, recent studies suggest that melatonin supplementation 
could be an efficient therapeutic approach in the context of obesity. In the present 
review, we have amalgamated the evidence so far available on physiological effects 
of melatonin supplementation in obesity therapies, addressing its effects upon 
neuroendocrine systems, cardiometabolic biomarkers and body composition. Most 
studies herein appraised employed melatonin supplementation at dosages ranging 
from 1 to 20 mg/day, and most studies followed up participants for periods from 3 
weeks to 12 months. Overall, it was observed that melatonin plays an important role 
in glycaemic homeostasis, in addition to modulation of white adipose tissue activity 
and lipid metabolism, and mitochondrial activity. Additionally, melatonin increases 
brown adipose tissue volume and activity, and its antioxidant and anti-inflammatory 
properties have also been demonstrated. There appears to be a role for melatonin in 
adiposity reduction; however, several questions remain unanswered, for example 
melatonin baseline levels in obesity, and whether any seeming hypomelatonaemia or 
melatonin irresponsiveness could be clarifying factors. Supplementation dosage 
studies and more thorough clinical trials are needed to ascertain not only the relevance 
of such findings but also the efficacy of melatonin supplementation.  
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1. Introduction 
According to results from the National Health and Nutrition Examination Survey 
2013–2014 [1], more than 2 in every 3 adults in the United States were overweight or 
had obesity. In 2017 in England, over 64% of the adult population were overweight or 
obese [2]. It is estimated that the United Kingdom National Health Service spent £6.1 
billion on overweight and obesity-related ill-health in 2014 to 2015 [3]. Most 
significantly however, numbers are predicted to increase for both countries in the near 
and far future [4, 5], and the costs associated with obesity are simply unaffordable. It 
is believed that the exponential increase in obesity in recent times may be explained 
by likely synergistic interactions amongst increased calorie consumption, low 
nutritional value of foods, increased sedentariness, reduced time and quality of sleep, 
and epigenetic susceptibility [6-8]. 
The relationship between obesity and several other non-communicable 
diseases is becoming unarguably evident [6, 9]. Even if obese individuals do not have 
an associated diagnosis of hypertension, type II diabetes mellitus (T2DM) or 
dyslipidaemia, yet there is an approximate 49% increased risk for coronary heart 
disease; 7% increased risk for cerebrovascular diseases and 96% increased risk for 
heart failure [10]. A prospective cohort study demonstrated that every kg of weight 
gained annually over 10 years was associated with a 49% increased risk of developing 
T2DM. On the other hand, every kg of weight lost annually over the same period was 
associated with a 33% lowered risk of developing T2DM [11]. Despite being a well-
known disease and the importance of its treatment well elucidated, obesity remains a 
topic of global interest. The full elucidation of the aetiologies associated with obesity, 
which include factors as diverse as genetic, epigenetic, environmental [12, 13], 
psychological and social [14, 15], and the further advancement of effective 
pharmacological therapies [16] may, in tandem, increase the likelihood of successful 
management and possibly treatment. 
Melatonin, a pineal hormone, is a molecule associated in a way or another with 
probably all physiological systems, aiming to fulfil its functional integrative roles in 
central nervous system activity, sleep and wakefulness cycles, energy metabolism and 
thermoregulation, immune, reproductive, endocrine, cardiovascular, respiratory and 
excretory systems [17]. This highly pervasive, integrative physiological regulatory role 
attributed to melatonin adapts the organism to the present environmental challenges, 
by means of the so-called immediate effects. At the same time, melatonin equips the 
organism with the capacity to deal with future predictive events, by means of the so-
called prospective effects. Additionally, melatonin synchronizes the organism’s 
physiology and behaviour to the daily (circadian internal zeitgeber) and annual 
photoperiodical (seasonal synchronizer) cycles. 
Whilst the effectiveness of melatonin supplementation on improving sleep 
quality has been investigated [18-20], its supplementation has also been proposed as 
beneficial for the treatment of obesity and inherent metabolic dysregulations [21-25]. 
Such hypothesis is derived from a plethora of experimental studies and from a few 
clinical studies. Nevertheless, the actual role of melatonin as adjuvant for the treatment 
of obesity, if any, is far from being fully understood. In the present narrative review, we 
have identified and further discussed physiological pathways in which melatonin, or 
the lack of thereof, could be associated with energy metabolism and obesity. We have 
also attempted to discuss how melatonin supplementation could ameliorate the 
metabolic disturbances associated with obesity. 
 
2. Melatonin characteristics 
2.1. Biosynthesis and Pharmacokinetics of exogenous supplementation 
The light/dark environmental information is crucial for the regulation of 
melatonin endogenous biosynthesis. During the night most melatonin is synthesized, 
approximately 80%, reaching serum concentrations between 80 and 120 pg/mL [26], 
whilst during the day its concentration remains lower, around 10 pg/mL or less [27]. 
Salivary melatonin, a reliable and easily accessible biomarker, shows concentrations 
at around 4 pg/mL in dim-light melatonin onset (DLMO), which normally occurs 
between 19:30 and 22:00 in adults and between 19:00 and 21:00 in children (6 to 12 
years) [28]. Plasma melatonin concentration during DLMO is about three times the 
values obtained for salivary melatonin concentration, around ≤10 pg/mL [29]. 
Melatonin is endogenously synthesised from its precursor tryptophan. 
Melatonin production in the central nervous system is carried out mainly in 
pinealocytes, cells of the pineal gland, starting with the hydroxylation of tryptophan to 
5-hydroxytryptophan (5-HTP). A subsequent decarboxylation catalysed by the 5-
hydroxytryptophan decarboxylase generates serotonin (5-hydroxytryptamine (5-HT)). 
The arylalkylamine-N-acetyltransferase (AANAT) acetylates serotonin to N-
acetylserotonin (NAS), which is methylated by the acetylserotonin-O-
methyltransferase (ASMT), producing melatonin. 
Exogenous melatonin, on the other hand, is shown to feature rapid absorption 
and plasma distribution. Its plasma concentration peaks at approximately 50 minutes 
after oral administration, with half-life of approximately 45 minutes [30]. In healthy 
volunteers, 10 mg melatonin oral supplementation resulted in mean t1/2 absorption of 
6.0 (3.1) min, mean tmax of 40.8 (17.8) min, median (IQR) maximum concentration 
(Cmax) of 3,550.5 (2,500.5–8,057.5) pg.mL-1 and mean t1/2 elimination of 53.7 (7.0) 
min [31]. The same dosage administered intravenously showed a median Cmax of 
389,875.0 (174,775.0–440,362.5) pg.mL-1 and mean t1/2 elimination of 39.4 (3.6) min 
[31]. The rapid increase in plasma concentrations following intravenous as well as oral 
supplementation has influenced decision-making practice in therapies at secondary 
and tertiary healthcare levels, given the important antioxidant and hypnotic roles of 
melatonin, and as an important pharmacological aid in critically ill patients [32, 33].  
Lastly, melatonin oral supplementation is metabolised in the liver by the 
cytochrome P450 CYP1A2 enzyme [34], where a hydroxylation reaction converts 
melatonin to its main metabolite 6-hydroxymelatonin sulfate, also known as 6-
sulfatoxymelatonin [35, 36]. This metabolite, when measured in urine, has been used 
clinically as a biomarker in the fields of psychiatry [37, 38], gynaecology [22, 39] and 
sleep medicine [40, 41]. 
 
2.2. Mechanism of action and metabolic regulation 
Melatonin receptors are G protein-coupled receptors (GPCR), in which two 
types are found in humans and mammals (MT1 and MT2) and a third form (Mel1C) is 
found in fish, amphibians and birds [42, 43]. The melatonin MT1 receptor (also called 
Mel1a, ML1A or MTNR1A) consists of 350 amino acids, whilst the melatonin MT2 
receptor (also called Mel1b, ML1B or MTNR1B) consists of 362 amino acids [43]. 
Currently, melatonergic agonist drugs, such as agomelatine, ramelteon and 
tasimelteon, have been widely used in psychiatric (e.g. major depression), oncological 
(e.g. glioblastoma) and sleep diseases (e.g. insomnia) [44-46]. 
The systematic regulation induced by melatonin, from the binding to its 
receptors, varies according to each organ [47]. Our research group has recently 
discussed the effects of melatonin in the ovary and, amongst its various effects, 
melatonin activation reduces cyclic AMP (cAMP) levels in granulosa cells (GCs), 
resulting in lowered synthesis of androgenic hormones [22]. Furthermore, in the 
pancreas, melatonin reduces cAMP as well as cGMP levels, effects that control insulin 
and glucose homeostasis [48]. Such regulation, together with the circadian phase 
control, allows a rhythmic fluctuation in glucose tolerance that is increased in the early 
hours of the day and reduced at night [49, 50]. 
Regarding its other physiological effects, the antioxidant capacity of melatonin 
is mainly associated with increased production of antioxidant enzymes, including 
superoxide dismutase, catalase, glutathione and others, as well as its antioxidant 
effect per se [51, 52]. The anti-inflammatory role of melatonin is evidenced, amongst 
several pathways, through its inhibitory effect on NF-kB activity, identified in several 
diseases with pro-inflammatory aetiology, such as rheumatoid arthritis and 
osteoarthritis [53]. Melatonin has also been shown to inhibit the NLR Family Pyrin 
Domain Containing 3 (NLRP3), an important inflammatory mediator known to reduce 
the inflammatory cascade for the synthesis of pro-inflammatory cytokines [54]. 
 
3. Melatonin supplementation and adipose tissue 
3.1. Modulation of adipose tissue activity  
It has been demonstrated in rats that melatonin appears to induce lipolysis [55, 
56], which is further corroborated by findings of reduced lipolysis and increased 
lipogenesis in pinealectomized rats [57]. Mechanistically, melatonin administration not 
only reduces total body fat, but more specifically intra-abdominal, retroperitoneal, 
hepatic and visceral fat in experimental models [58]. The lipolytic mechanisms 
modulated by melatonin are illustrated in Figure 1. 
 
[Insert figure 1 here] 
 
Several animal studies have provided insights into the roles of melatonin on 
expanding brown adipose tissue (BAT) volume and metabolic capacity, as confirmed 
by research employing rats [59, 60], sheep [61], hamsters [62] and rabbits [63]. A 
recent study employing diet-induced obese rats found that the time of the day in which 
melatonin was administered had an impact on BAT metabolism, being more effective 
late in the evening as compared to morning administration [64]. 
The relationship between melatonin and BAT activity has been investigated in 
humans [58]. Recently, Halpern et al (2019) demonstrated in a small but important 
proof-of-concept study that the daily administration of 3 mg melatonin for 3 months 
increased BAT volume in the four patients investigated, who presented melatonin 
deficiency due to either radiotherapy or surgical removal of their pineal gland [65]. 
Putatively, the activity of melatonin upon BAT appears to be mediated by MT2 
receptors [66], which were firstly identified in human retina by Dubocovish in 1985 [67] 
and cloned by Reppert et al ten years later [68]. 
The hypothesis that melatonin supplementation could possibly modulate BAT 
activity in overweight and obese individuals has been proposed, but to the best of our 
knowledge no clinical trial has yet been carried out to investigate this specific effect. 
On those grounds, further research is imperative to elucidate the roles of melatonin 
upon BAT activity in obesity, since this role has been currently explored as a clinical 
target in therapies for obesity and other metabolic disorders, including T2DM [69, 70]. 
 
3.2. Body composition: weight and fat loss 
Melatonin supplementation hindered weight gain in a model of high-fat diet 
obese rats [71]. In the same study, pinealectomized rats developed not only obesity 
but also T2DM, with melatonin supplementation partially mitigating the high glucose 
levels observed. The effects of melatonin supplementation as modulator of body 
composition have been previously discussed in previous studies [72-74]. In a double-
blind randomised clinical trial (RCT), Amstrup et al [75] reported that a group of 
postmenopausal eutrophic women diagnosed with osteopenia and treated with 
melatonin (1 and 3 mg/day) for 12 months showed improved body composition, 
measured by dual X-ray absorptiometry, as compared to the women who received 
placebo [75]. The researchers also found at the end of the 12 months study a 6.9% 
reduction in fat mass combined with a 5.2% increase in lean mass in the melatonin-
receiving group. However, as that study did not report dietary patterns nor levels of 
physical activity, caution is required before any clinical recommendation can be made. 
In an investigation associating melatonin supplementation (10 mg/day 1 h 
before bedtime) combined with calorie-restricted diet (1,000–1,200 kcal/d for women 
and 1,400–1,600 kcal/d for men) in adult patients with obesity, the intervention with 
melatonin was able to enhance weight loss further, from 113.6 to 105.9 kg, as 
compared to the placebo-receiving group, from 114.4 to 109.8 kg. Additionally, 
malondialdehyde (MDA) levels, an oxidative stress biomarker, had greater reduction 
in the melatonin group, from 34.3 to 24.5 nmol/g Hb, when compared to placebo, from 
30.1 to 27.4 nmol/g Hb [76]. The apparent reduction of oxidative stress induced by 
melatonin observed in this study may suggest an important therapeutic approach for 
obese patients, since exacerbated oxidative stress induced by obesity is related to a 
greater risk for insulin resistance and increased accumulation of abdominal fat [77-
79]. 
Walecka-Kapica et al [80] found a significant reduction in body mass index 
(BMI) in postmenopausal women (mean age 56.9 ± 5.3) with high (from 29.62 to 27.88 
kg/m²; p<0.001) and normal (from 22.07 to 21.86 kg/m²; p<0.05) body weight under 
combined therapy of melatonin supplementation (5 mg/day for 24 weeks) and a 
balanced diet of 1,500 kcal/d. In addition to this effect on body composition, 
participants who received melatonin supplementation showed improved sleep quality, 
measured by the insomnia severity index (ISI). In their investigation [80] and in another 
one published by the same research group [81], a significant relationship was reported 
between decreased levels of 6-sulfatoxymelatonin and higher BMI in postmenopausal 
overweight women. We recently emphasized the importance of 6-sulfatoxymelatonin 
as a biomarker in the field of gynaecology [22] and, in conjunction with the findings of 
Walecka-Kapica et al, we reemphasize its usefulness as a measurable tool in clinical 
practice, as is in the case of women suffering with hormone dysregulation. In another 
study involving postmenopausal overweight women, melatonin supplementation at a 
dosage of 5 mg/day associated with fluoxetine at 20 mg/day for 24 weeks resulted in 
improved sleep quality, in addition to reduced appetite and BMI, from 30.9 to 26.3 
kg/m² [82].  
In 2014, Romo-Nava et al investigated in a RCT the effects of melatonin 
supplementation in patients suffering with bipolar disorder or schizophrenia and 
treated with second-generation antipsychotics [83], which are known by weight gain 
as one of their textbook side effects [84]. After eight weeks of placebo or melatonin 
supplementation at 5 mg/day, the researchers found that the placebo-receiving group 
gained significantly more weight (2.2 kg) than the melatonin-receiving group (1.5 kg). 
Olanzapine is one of the various second-generation antipsychotic drugs currently 
available [84], and most interestingly, Modabbernia et al [85] found in a RCT a 
protective effect of melatonin supplementation against weight gain induced by 
olanzapine treatment. Schizophrenia patients treated with olanzapine and 
supplemented with melatonin at the dosage of 3 mg/day for 8 weeks gained 2.2 kg 
body weight, as compared to the 5.4 kg body weight gain observed in the matched 
placebo-supplemented group [85]. The studies of Amstrup [75], Romo-Nava [83] and 
Modabbernia [85] did not report data on dietary intake or levels of physical activity. 
The question whether melatonin has a direct effect upon fat levels, or whether the 
changes in body weight observed were the result of an indirect pathway associated 
with decreased appetite or increased metabolic rate, remain unanswered. Further 
studies are needed to fully elucidate the role of melatonin in protecting against weight 
gain induced by antipsychotic pharmacotherapy. 
In the opposite direction to what has so far been discussed in this section, other 
studies have shown that melatonin supplementation have not ameliorated body 
composition in obese women [86], neither in diabetic [87] nor in metabolic syndrome 
[88] patients. The clinical trials that have investigated the effects of melatonin 
supplementation on body composition appraised in the present study are summarized 
in Table 1. Several studies have not reported data on dietary intake nor levels of 
physical activity and are noticeably different in their methodologies. For those reasons, 
additional comprehensive clinical trials are required to further elucidate melatonin 
actions in energy metabolism. 
 
[Insert table 1 here] 
 
Two recent meta-analyses have appraised clinical trials focusing on body 
composition and melatonin supplementation. In the meta-analysis of Mostafavi and 
colleagues published in 2017 [89], which covered seven clinical trials and a total of 
244 participants based on Mostafavi’s inclusion criteria, melatonin supplementation 
alone was ineffective in inducing weight loss, but showed a positive effect when 
combined with other strategies. A more recent meta-analysis, published in 2019, 
showed that melatonin supplementation alone improved selected lipid biomarkers but 
was ineffective in inducing weight loss [90]. Based on their inclusion criteria, that meta-
analysis selected 6 clinical trials and a sample of 338 individuals for effects on weight 
loss. The authors themselves recognised a few limitations in their selection of clinical 
trials, such as low sample size, lack of clarity in the blinding process of the studies 
appraised and selection of participants, as well as heterogeneity attributed to the 
differences in characteristics, including range of diseases, amongst the selected 
studies. 
 
4. Musculoskeletal metabolism and lean body mass 
The adipose tissue and skeletal muscle are the two largest insulin-responsive 
tissues in the human body, and responsible for the secretion of adipokines and 
myokines, respectively [91]. Both families of bioactive molecules act in synergy to 
regulate a vast range of biochemical pathways involved in energy metabolism and lipid 
storage, and it is widely accepted that disturbances in the lean/fat mass ratio lead to 
several metabolic diseases. Muscle mass is protective against not only obesity but 
also other metabolic disturbances, including sarcopenic obesity [92], which is 
characterized by impaired function and strength of skeletal muscle [93]. The main 
aggravating factors in sarcopenic obesity include exacerbated oxidative stress and 
skeletal muscle inflammation [94]. On those grounds, an adequate programme of 
physical activity associated with specific nutritional interventions that focus on muscle 
protection is a determining strategy in sarcopenic obesity [92, 95]. The previously 
described antioxidant properties of melatonin could positively influence myocyte 
metabolism, in which redox signalling molecules modulate several physiological 
processes [96]. The study of Amstrup et al [75], referred earlier, found a small but 
important increase of 2.6% in lean body mass, adjusted for BMI, in the melatonin group 
as compared to placebo. A shortfall, however, is that Amstrup did not report physical 
activity patterns or dietary habits. 
More recently, Rondanelli et al investigated in a RCT the effects of melatonin 
supplementation at the dosage of 1 mg/day, associated or not with essential amino 
acid supplementation at the dosage of 4 g/day for 4 weeks, in a total of 159 elderly 
hospitalized sarcopenic patients, segregated in that study into 4 groups [97]. The 
researchers found that melatonin-only supplementation worsened protein metabolism 
by decreasing albumin levels, but also that melatonin when combined with essential 
amino acid supplementation improved fat-free mass [97]. A few limitations in the 
design of Rondanelli’s study may be identified. Firstly, plasma albumin per se is not 
the best biomarker for muscle status [98], a fact that the authors themselves 
appreciate in their study. Secondly but most importantly, despite the randomisation 
been made by software, it is an unfortunate fact that gender distribution was not 
homogeneous across the four groups: the ratio women/men was 2.4 in the placebo 
group, 6.0 in the melatonin-only group, 3.4 in the essential amino acid-only group, and 
1.4 in the essential amino acid plus melatonin group. It is possible to speculate that 
the differences in gender distribution across the four groups may have influenced the 
results on body composition and lean body mass, and on those grounds the observed 
effects of melatonin supplementation may not be a true representation of its actual 
metabolic potential for that population.  
Other studies have investigated the roles of melatonin on muscle homeostasis 
by focusing on its antioxidant and anti-inflammatory actions, as well as its indirect 
effects by means of ameliorating chronoregulation [99, 100]. However, further clinical 
trials are needed to thoroughly investigate the effects of melatonin supplementation 
not only on musculoskeletal metabolism, but also in other systems with low fat content, 
including skin, blood cells, bones, and internal organs in general. 
 
5. Cardiovascular and lipid profile outcomes 
A few review papers have reappraised the effects of melatonin supplementation 
in the field of cardiology [101-103]. As an adjuvant antihypertensive agent, melatonin 
has been proposed as a modulator of oxidative stress at vascular endothelium level 
[104]. In a small population of healthy volunteers, the acute effects of a single 3 mg 
dose of melatonin were tested. As a result, forearm blood flow and vascular 
conductance were increased 45 minutes after its ingestion, as compared to the same 
individuals taking placebo a few days later [105]. Such effects may be explained by 
activation of MT2 receptors and subsequent vasodilation of the capillary bed [47, 106]. 
Scheer et al [107] found that melatonin supplementation at the dosage of 2.5 
mg/day 1 hour before bedtime for three weeks reduced systolic blood pressure by 6 
mmHg and diastolic blood pressure by 4 mmHg in a group of 16 men suffering with 
untreated essential hypertension. Along similar lines, Koziróg et al [88] observed that 
melatonin supplementation at the dosage of 5 mg/day 2 hours before bedtime for two 
months reduced systolic blood pressure by nearly 13 mmHg and diastolic blood 
pressure by 6.5 mmHg in a group of metabolic syndrome patients unresponsive to 
positive lifestyle interventions. 
Corroborating the evidence referred above, a recently published systematic 
review and meta-analysis of RCTs showed a small but statistically significant effect of 
melatonin supplementation on blood pressure in patients with metabolic disorders 
[108]. The authors found that overall 2 to 10 mg/day of melatonin supplementation 
during intervention periods ranging from 4 to 12 weeks were effective in reducing 
systolic blood pressure by 0.87 mmHg, and diastolic blood pressure by 0.85 mmHg, 
in patients with metabolic disorders [108]. 
It has been demonstrated that not only blood pressure can be influenced by 
melatonin supplementation, but so can lipid profile and antioxidant status. Koziróg et 
al [88], apart from their findings on blood pressure described earlier, also found 
significantly lowered low-density lipoprotein cholesterol (LDL-c) concentration, from 
149.7 mg/dL to 139.9 mg/dL. In the same study, the authors found reduced levels of 
total cholesterol, from 233.4 mg/dL to 220.7 mg/dL, and triglycerides, from 201.9 
mg/dL to 166.6 mg/dL. Such findings however, although clinically relevant, did not 
reach statistical significance. Antioxidant capacity was also found to be improved in 
that study, evidenced by significantly increased levels of catalase and decreased 
levels of thiobarbituric acid reactive substrates (TBARS) [88]. 
A recently published systematic review and meta-analysis of RCTs 
investigating the effects of melatonin supplementation on lipid profile showed that 
supplementation at dosages higher than 8 mg/day for periods longer than 8 weeks 
significantly improved lipid profile, including reduced triglyceride levels by 31.5 mg/dL 
and reduced total cholesterol levels by 18.5 mg/dL [109]. In the same study, small 
changes were observed in LDL-c and high-density lipoprotein cholesterol (HDL-c) 
levels, but which did not reach statistical significance. The population investigated in 
that systematic review was varied, including not only healthy volunteers but also 
patients suffering with non-alcoholic steatohepatitis, metabolic syndrome, 
hypercholesterolemia, schizophrenia and bipolar disorder [109]. 
 
6. Biochemical modulation of hepatic parameters 
Obesity is directly related to higher prevalence of non-alcoholic fatty liver 
disease (NAFLD). Whilst the prevalence of NAFLD in the general population is 15 to 
30%, its prevalence in obese individuals ranges from 50 to 90%, in which the higher 
the BMI the higher the prevalence [110]. Several experimental [111-113] and review 
studies [114-117] have reported favourable effects of melatonin administration against 
liver diseases, attributed mainly to the well-described antioxidant, anti-inflammatory 
and DNA-protective roles of melatonin. 
Correspondingly, a recent meta-analysis of RCTs reported appealing results of 
melatonin supplementation on the traditional clinical panel used in the management 
of liver diseases, such as a reduction in gamma-glutamyl transferase (GGT) (-33 IU/L) 
and alkaline phosphatase (ALP) (-8 IU/L) levels [118]. On the other hand, no significant 
difference was detected in the levels of alanine aminotransferase (ALT), whilst there 
was an increase in aspartate aminotransferase (AST) (+2 IU/L) levels but with an 
absence of clinical significance. The patients included in this meta-analysis had a 
diagnosis of NAFLD or non-alcoholic steatohepatitis.  
In a RCT [119] investigating patients with NAFLD (n = 24) supplemented with 
6 mg/day melatonin for 12 weeks significantly reduced levels of ALT (60 to 41 IU/L) 
and AST (35 to 30 IU/L), in comparison with the placebo group (n = 21). Whilst GGT 
levels did not change significantly, the authors have considered a tendency for 
reduction (35 to 31 IU/L, p = 0.07). Interestingly, when comparing baseline vs. end of 
intervention, the melatonin-receiving group showed in average decreased body weight 
by 1.3 kg (85.5 to 84.2 kg) and abdominal circumference by 2 cm (107 to 105 cm), 
without changes in calorie intake. Notwithstanding the favourable results herein 
described, no evidence yet available corroborates melatonin supplementation for the 
management of liver cirrhosis, an advanced stage of NAFLD. 
 
7. Glucose homeostasis and insulin sensitivity 
Melatonin is known to participate in the intracellular processes that regulate 
insulin secretion and blood glucose homeostasis by its binding to MT1 and MT2 
receptors in the pancreatic beta cell [120, 121]. It is also known that genetic variants 
of the MTNR1B gene, which encodes the MT2 melatonin receptor, have been 
associated with the development of insulin resistance and T2DM [122, 123]. 
Experimental studies further corroborate the properties of melatonin supplementation 
in improving insulin sensitivity and consequently glycaemic control [124-126]. 
Similarly, in humans the effects are also promising. A recent RCT [127] investigating 
melatonin therapy for 12 weeks in T2DM patients with coronary heart disease found 
that melatonin significantly decreased fasting plasma glucose (−29 vs.−5.6 mg/dL), 
serum insulin (−2.2 vs. +0.7 μIU/mL), and improved the homeostasis model of 
assessment-estimated insulin resistance (HOMA-IR) (−1.0 vs. +0.01), as compared to 
the placebo group. 
A recent systematic review and meta-analysis of RCTs investigating the effects 
of melatonin supplementation at dosages ranging from 3 to 10 mg/day during periods 
ranging from 4 to 24 weeks upon glycaemic control showed significant reduction in 
fasting glucose levels and significant elevation of the quantitative insulin sensitivity 
check index (QUICKI) [128]. The same study however did not find significant effects 
on insulin levels, HOMA-IR, nor haemoglobin A1c levels. The population investigated 
in that systematic review included patients suffering with endocrine disorders including 
T2DM, metabolic syndrome, non-alcoholic steatohepatitis, as well as neuropsychiatric 
disorders [128]. 
Whilst previous reviews discussed promising results of melatonin 
administration on metabolic parameters [21, 103], other studies have observed 
impairments in glucose levels. Working on an acute intravenous glucose tolerance 
test, Cagnacci et al [129] noted that 1 mg melatonin reduced insulin-dependent, but 
not insulin-independent, glucose utilisation in postmenopausal women. In an oral 
glucose tolerance test study, a single 5 mg dose of melatonin reduced glucose 
tolerance when administered in the morning, as well as in the evening, in healthy 
women (n = 21) [130]. Furthermore, morning melatonin supplementation increased 
the plasma glucose incremental area under the curve (AUC) by 186% and Cmax by 
21%. When melatonin was administered in the evening, glucose AUC and Cmax were 
raised by 54% and 27%, respectively. 
However, in order to properly understand these apparent contradictory results 
it is necessary to understand melatonin modes of action and its effects [17, 23]. In 
diurnal active species, humans for example, night is the rest/fasting daily phase and 
the expected physiological immediate effects of melatonin include induction of sleep, 
inhibition of appetite and metabolic adaptation to the fasting state, which includes 
hepatic insulin resistance, inhibition of insulin release, gluconeogenesis, amongst 
others. In the studies cited above [129, 130], following melatonin administration, its 
immediate effects were measured either in the morning or in the evening and, as 
expected, the immediate effects of melatonin are inhibition of insulin release and 
insulin resistance. However, it should be considered that in health physiological 
conditions melatonin is at its lowest levels during the day. This indicates that, when 
considering long-term melatonin therapy, its administration should preferentially be 
nocturnal, since to date, no chronic study has yet observed such impairments in 
glucose and insulin homeostasis attributed to melatonin supplementation. 
Impaired melatonin function has been described in rare diseases characterized 
by severe insulin resistance, for example Rabson–Mendenhall syndrome [131], which 
suggests a protective role for melatonin over pancreatic activity. The aetiology of 
Rabson–Mendenhall syndrome is associated with extreme hyperinsulinemia induced 
by mutations in the insulin receptor gene, and the main pathophysiological 
manifestations include abnormal glucose homeostasis, pineal hyperplasia, elevated 
levels of urinary melatonin metabolite [132, 133], dysmorphism of the head, face and 
nails, alongside the development of acanthosis nigricans [133, 134]. Regarding the 
latter, it was recently described that melatonin supplementation at the dosage of 3 
mg/day for 12 weeks for obese patients improved insulin sensitivity and inflammatory 
biomarkers, and reduced the intensity of acanthosis nigricans of the neck and axilla 
[135], a manifestation strongly associated with metabolic syndrome in adults [136] and 
children [137]. 
 
8. Mitochondrial modulation: oxidative stress and antioxidant potential 
One of the remarkable physiological roles of melatonin is its capacity to mitigate 
oxidative stress and to balance antioxidant and oxidant molecules around the 
mitochondrion, a cellular source of several antioxidant enzymes and reactive oxygen 
species [138, 139]. Several experimental studies have already sought to understand 
the antioxidant potential of melatonin in various diseases, including Alzheimer's 
disease [140], cardiovascular disease [141], obesity and T2DM [142]. In the clinical 
field, supplementation with 5 mg of melatonin for 30 days in elderly T2DM patients 
improved the oxidative response by increasing the erythrocytic activity of superoxide 
dismutase-1 and decreasing oxidative biomarkers, such as the erythrocytic 
concentration of MDA [87].  
The protective effects of melatonin on mitochondrial oxidation-reduction 
modulation appear to be promising in individuals affected by cardiometabolic 
disorders. Raygan et al [127], working with patients with coronary disease and 
receiving melatonin at a dosage of 10 mg/day for 12 weeks, found increased levels of 
glutathione and concomitantly decreased levels of oxidative biomarkers, such as MDA 
and protein carbonyl concentrations, compared to the placebo group. Furthermore, 
the melatonin-receiving group showed increased nitric oxide levels, whilst this 
parameter was reduced in the placebo group, which can be seen as a positive effect 
of melatonin upon vascular tonus. Given that increased oxidative stress is a major 
underlying factor in the pathogenesis of obesity and obesity-related diseases, and that 
melatonin supplementation may at least partially mitigate such metabolic 
dysregulations, further clinical attention should be considered regarding the latter so 
as to contribute to the treatment of those conditions. 
 
9. Therapy of obesity: open questions about melatonin supplementation as a 
possible tool 
Historically and still currently, several pharmacological agents have been 
employed for the management and or treatment of obesity. For example, Franz et al 
[143] in their meta-analysis found an average of 5% to 9% weight loss during the first 
6 months of interventions based on low calorie diets, combined or not with orlistat or 
sibutramine, but the weight losses observed tended to plateau after 6 months, and in 
several instances were not maintained. Additionally, although paramount for 
improvement in body composition and overall health, various research groups have 
independently found very similar results: physical activity only has very little effect on 
BMI [144, 145]. The overall consensus amongst practitioners is that the triad physical 
activity + dietary improvement + weight loss medication is much more effective than 
any of these strategies alone for long term, maintained weight loss. 
It may well be possible that melatonin supplementation is an effective adjuvant 
in therapies for obesity where the affected individuals present lower levels of melatonin 
to begin with, or are somehow irresponsive to their endogenous melatonin. Further 
long-term trials recruiting obese subjects investigating the variables nutrition, exercise, 
melatonin supplementation and its biomarkers would be extremely helpful to expand 
our knowledge of melatonin as potential adjuvant in the treatment of obesity. Finally, 
some open questions on the therapeutic applicability of melatonin supplementation in 
the management of obesity and its inherent comorbidities are presented (Table 2). 
 
[Insert table 2 here] 
 
10. Safety of supplementation 
Firstly, upon analyses of experimental models, hyper doses of melatonin 
showed no signs of toxicity and lethality [146, 147]. Such safety has also been 
demonstrated in pregnant rats, demonstrating an absence of toxicity for both the 
mother and the foetus in doses up to 200 mg/kg/day [148]. 
In humans, several studies have deemed melatonin supplementation to be 
safe, and no dramatic side effects or toxicological issues have been reported within 
the dosages investigated [149-151]. Melatonin supplementation at a dosage of 50 
mg/day—a dose considered high—for 2 weeks to elderly patients suffering with 
Parkinson's disease was deemed to be safe, with 2 out of 40 subjects reporting 
daytime tiredness as a side effect [20]. A meta-analysis of 8 RCT supplementing 20 
mg/day of melatonin to cancer patients showed no significant side effects attributed to 
melatonin [152]. Another recent meta-analysis, involving children and adolescents 
affected by sleep onset insomnia, showed that melatonin supplementation was a well-
tolerated agent at doses of 1 to 6 mg/day [153]. The most common adverse effects 
seen are dizziness, headache, nausea, daytime sleepiness, transient episodes of 
numbness and stomach pain. 
Alarmingly however, even though as not the therapeutic target of our 
hypothesis, three recent reports of infant death have been associated with melatonin 
[154, 155]. It is worth mentioning that other factors might have, in a way or another, 
contributed to the deaths, and also that the melatonin concentrations detected in the 
peripheral blood of the victims were incredibly high, 13 ng/mL and 210 ng/mL in the 
report of Labay et al [154] and 1,400 ng/mL in the report of Shimomura et al [155]. 
What appears to be cases of melatonin overdose justify the development of more 
detailed overdosage studies in animal models. 
 
11. Conclusion 
Melatonin is a potential, multifaceted candidate for the management of obesity 
due to its biological effects on insulin and adipose tissue metabolism, lipolysis and 
mitochondrial capacity, added to its antioxidant and anti-inflammatory properties. 
Melatonin supplementation has been proposed as an adjuvant in the treatment of 
obesity and associated metabolic diseases including T2DM, NAFLD, hypertension 
and dyslipidaemia. RCTs appraised in the present review employed in average 1 to 
20 mg/day of melatonin supplementation for periods ranging from 3 weeks to 12 
months; however, not all trials found evidence of weight loss.  
It remains to be elucidated whether melatonin supplementation for the 
treatment of obesity is effective only for individuals who show hypomelatonaemia or 
melatonin irresponsiveness at baseline. If so, one begs the question as to why 
melatonin levels are low or inefficient to begin with. Viewed collectively, the proposed 
role of melatonin as a weight loss aid is still on debate, and so is its safety. Further 
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